Pharmacy Daily | Actavis Valeant deal

ACTAVIS and Valeant have overnight announced a settlement agreement in the USA which resolves outstanding patent litigation in relation to a US FDA New Drug Application by Actavis for Clindamycin and Tretinoin Gel, a generic version of Valeant’s Ziana, as well as for Imiquimod Cream, a generic version of Zyclara. Under the terms of the agreement Actavis may launch its generic Ziana in Jul 2016, while a generic Zyclara can be launched by Actavis in Jan 2019. The confidential settlement will also see Valeant receive a share of the proceeds from the generic products sold under the agreements. Ziana is a lincosamide antibiotic and retinoid combination product indicated for the topical treatment of acne, while Zyclara is a prescription medicine used for the treatment of actinic keratosis on the full face or balding scalp in adults with a normal immune function.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 11 Apr 13
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Apr 13